Carisma Therapeutics
Update in progressCARM (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Carisma Therapeutics, Inc. is a biotechnology company developing therapies for liver fibrosis and cancer. Its pipeline includes CT-2401 in preclinical development for liver fibrosis and CT-1119, a mesothelin-targeted CAR-Monocyte in Phase 1 for advanced mesothelin-positive solid tumors. It also pursues in vivo CAR-M cell therapy for solid tumors and collaborates with ModernaTX on oncology gene therapies. Founded 2016 as CARMA Therapeutics; renamed Carisma in 2017. Based in Philadelphia, PA.
Company score
- Sentiment
- -0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- -0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- Founded2016
- Employees46
- Websitewww.carismatx.com
Identifiers
- ISINUS14216R1014
- FIGIBBG001J2N453
- CUSIP14216R101
- CIK0001485003